Tagged with US

Austria Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role of training clinics in establishing a vertical business model and provides an overview of the company’s growing global reach, namely…

Austria Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and…

Austria Michael Stampfer, managing director of the Vienna Science and Technology Fund (WWTF), the only private, non-profit organization in Vienna dedicated to funding scientific research, discusses the challenges scientific research faces in Austria and how the organization helps bridge the gap between academia and industry. Furthermore, he illustrates the steps taken…

Austria Michaela Latzelsberger, country manager of Coloplast Austria, a Danish medical device company focused on ostomy, continence and wound care, discusses the challenges of launching innovative medical devices on the Austrian market, especially considering the system’s undervaluation of quality of life data. Furthermore, she provides an overview of how Coloplast Austria…

Austria Urs Weber, general secretary of the Swiss Chamber of Commerce in Austria, discusses the role of the chamber as a networking facilitator between Austrian and Swiss companies as well as the similarities and differences between both countries’ business cultures. Furthermore, he explains what makes Austria an attractive investment destination and…

Austria Heidrun Katholnigg, executive director of global clinical development Europe for Celerion, a global CRO that specialises in phase I, II and III clinical trials, discusses the acquisition of Assign Group by Celerion in 2016 and the importance of Austria in managing European clinical operations. Furthermore, she highlights the favourable clinical…

Austria Ulrich Schlick, deputy managing director of the German Chamber of Commerce in Austria, discusses the Chamber’s role in facilitating business opportunities for German companies in Austria and vice versa. He also provides an overview of the cultural ties and differences between the countries and the potential of Austria for German…

Austria Bernd Grabner, board member of Jacoby GM pharma, a leading Austrian wholesaler, provides an in-depth look into the historical merger of family owned Jacoby, GM pharma and Kӧgl Pharma as well as the moves being made to bolster a vertically integrated business model. Furthermore, he gives an overview of the…

Austria Barbara Fritsche-Surchat, general manager of Servier Austria, a leading innovative French company looking to bolster its global oncology presence, provides an in-depth analysis of the balancing act between pricing and market access in the Austrian healthcare system as well as how the company’s global oncology vision has influenced Austrian operations.…

Austria Martin Spatz, country manager of QuintilesIMS Austria, the global leader in healthcare market research, discusses the diverse range of services they provide to the two separate entities of the of Austrian healthcare system: the retail and hospital sectors. Furthermore, he provides an in-depth look at the positive impact of accurate…

Austria Rudolf Wessely, CEO and founder of Gynial, the Austrian leader in oral contraceptives, elaborates on the company’s incredibly fast market penetration since 2007 and explains his expertise in the contraceptive field. Furthermore, he discusses the importance of open communication with gynaecologists and Gynial’s unique product philosophy as well as the…

Austria Bernhard Wittmann, managing director of Sigmapharm and MoNo, discusses the company’s product portfolio and the diverse tailored services for their partners. Furthermore, he provides an in-depth look into MoNo’s new 20 million EUR (24 million USD) CMO production plant that will be completed in 2019. The ten-fold increase in capacity…